GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » 3-Year EPS without NRI Growth Rate

Immunovant (Immunovant) 3-Year EPS without NRI Growth Rate : -1.90% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant 3-Year EPS without NRI Growth Rate?

Immunovant's EPS without NRI for the three months ended in Dec. 2023 was $-0.36.

During the past 3 years, the average EPS without NRI Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Immunovant was -1.90% per year. The lowest was -1.90% per year. And the median was -1.90% per year.


Competitive Comparison of Immunovant's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Immunovant's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Immunovant's 3-Year EPS without NRI Growth Rate falls into.



Immunovant 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Immunovant  (NAS:IMVT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Immunovant 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Immunovant's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant (Immunovant) Business Description

Industry
Traded in Other Exchanges
N/A
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
William L. Macias officer: Chief Medical Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett officer: Chief Financial Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mark S. Levine officer: Chief Legal Officer 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Jay S Stout officer: Chief Technology Officer C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Rita Jain officer: Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018